Alpha-tocopherol quinone: Phase IIa started

Last month, Penwest began a double-blind, placebo-controlled, U.S. Phase IIa trial to evaluate 1.0 and 1.5 mg/day oral A0001 given for 28 days in 42 patients. Penwest has exclusive, worldwide rights t...